Lifecore Biomedical, Inc. LFCR Income Statement
| TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | TTM Q4 '24 | ||
|---|---|---|---|---|---|---|
| $128.87M-1.1% | $130.31M-0.4% | $130.86M+1.9% | $128.45M+0.1% | $128.26M+5.5% | ||
| $88.57M+2.1% | $86.72M+1.8% | $85.22M+1.5% | $83.94M-2.9% | $86.41M-3.1% | ||
| $40.3M-7.5% | $43.59M-4.5% | $45.64M+2.5% | $44.51M+6.4% | $41.85M+29.3% | ||
| 31.3%-2.2pp | 33.4%-1.4pp | 34.9%+0.2pp | 34.7%+2.0pp | 32.6%+6.0pp | ||
| $8.26M-0.7% | $8.32M-1.5% | $8.44M-2.0% | $8.62M+0.5% | $8.58M+0.5% | ||
| $44.86M-6.7% | $48.11M+0.3% | $47.98M+3.8% | $46.2M+13.8% | $40.61M-0.2% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | -$1.28M+47.3% | -$2.42M+21.5% | -$3.09M-1.1% | -$3.05M-9.8% | ||
| -$38.67M— | —— | —— | —— | —— | ||
| $43K— | —— | —— | —— | —— | ||
| -$38.72M— | —— | —— | —— | —— | ||
| -30%— | —— | —— | —— | —— | ||
| -$1.23— | —— | —— | —— | —— | ||
| -$15.66M— | —— | —— | —— | —— | ||
| -12.2%— | —— | —— | —— | —— | ||
| -$23.69M— | —— | —— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Lifecore Biomedical, Inc.'s revenue?
- Lifecore Biomedical, Inc. (LFCR) generated $125.9M in revenue over the trailing twelve months, down 3.8% year over year.
- Is Lifecore Biomedical, Inc. profitable?
- Lifecore Biomedical, Inc. is not currently profitable: it reported a net loss of $40.9M over the trailing twelve months, a -30.0% net margin.
- What are Lifecore Biomedical, Inc.'s profit margins?
- Gross margin is 31.3% and operating margin is -14.5%, with a -30.0% net margin.
- What is Lifecore Biomedical, Inc.'s earnings per share?
- Lifecore Biomedical, Inc.'s diluted EPS over the trailing twelve months is $-1.17.
- Where does Lifecore Biomedical, Inc.'s income statement data come from?
- Every line is extracted from Lifecore Biomedical, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
